MHLW To Expand Drug Application Consultation Services July 1, But With A Price Tag For Industry
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare established a panel to improve the Pharmaceuticals and Medical Devices Agency's consultation services as one measure to eliminate Japan's drug and medical device lag, and the agency is expected to expand the range and number of consultations starting this year
You may also be interested in...
Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule
Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines
TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule
Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
The new openness provides opportunities for drug makers because it is no longer necessary to delegate all work to a Japanese partner, but the message is slow getting out.